Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice

Sleep

Volumn 33, Issue 7, 2010, Pages 930-942

  Okuro, Masashi ^a   Fujiki, Nobuhiro ^a   Kotorii, Nozomu ^a   Ishimaru, Yuji ^a   Sokoloff, Pierre ^b   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY   (United States)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Caffeine; Cataplexy; Mice; Modafinil; Narcolepsy; Paraxanthine

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ATAXIN 3; CAFFEINE; MODAFINIL; OREXIN; PARAXANTHINE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BODY TEMPERATURE; DRUG EFFECT; DRUG POTENCY; ELECTROMYOGRAPHY; GENOTYPE; HYPERSOMNIA; HYPOTHERMIA; LOCOMOTION; MOUSE; MULTICHANNEL RECORDER; NARCOLEPSY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SLEEP; TRANSGENIC MOUSE; WAKEFULNESS;

EID: 77954361234     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/33.7.930     Document Type: Article

References (30)

1. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 2004;61:857-72.
2. Nishino S, Mignot E. Pharmacology of CNS stimulants. In: Bassetti C, Billiard M, Mignot E, eds. Narcolepsy and hypersomnia. New York: Informa Healthcare USA, 2007:513-30.
3. Kennedy JS, Leduc BW, Scavone JM, Harmatz JS, Shader RI, Greenblatt DJ. Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods. J Chromatogr 1987;422:274-80.
4. Lelo A, Kjellen G, Birkett DJ, Miners JO. Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine. J Pharmacol Exp Ther 1989;248:315-9. (Pubitemid 19063507)
5. Berthou F, Guillois B, Riche C, Dreano Y, Jacqz-Aigrain E, Beaune PH. Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica 1992;22:671-80.
6. Chou CC, Vickroy TW. Antagonism of adenosine receptors by caffeine and caffeine metabolites in equine forebrain tissues. Am J Vet Res 2003;64:216-24.
7. Benowitz NL, Jacob P 3rd, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 1995;58:684-91.
8. Undem BJ. Pharmacotherapy of asthma. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The pharmacological basis of therapeutics, 11th ed. New York: McGraw-Hill Professional, 2005:727-36.
9. Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, Michel PP. Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 2008;74:980-9.
10. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30:345-54.
11. Fujiki N, Cheng T, Yoshino F, Nishino S. Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice. Exp Neurol 2009;217:46-54.
12. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991;38:63-7.
13. Chikahisa S, Sano A, Kitaoka K, Miyamoto K, Sei H. Anxiolytic effect of music depends on ovarian steroid in female mice. Behav Brain Res 2007;179:50-9.
14. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987;92:180-5.
15. Silva RH, Frussa-Filho R. The plus-maze discriminative avoidance task: a new model to study memory-anxiety interactions. Effects of chlordiazepoxide and caffeine. J Neurosci Methods 2000;102:117-25.
16. Kushida CA, Baker TL, Dement WC. Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electro Clin Neurophysiol 1985;61:61-70.
17. Rechtschaffen A, Kales A, eds. A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. Washington, DC: National Institutes of Health, 1968.
18. Logan L, Seale TW, Carney JM. Inherent differences in sensitivity to methylxanthines among inbred mice. Pharmacol Biochem Behav 1986;24:1281-6. (Pubitemid 16067411)
19. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997;283:757-69.
20. Willie JT, Renthal W, Chemelli RM, et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 2005;130:983-95.
21. Durcan MJ, Morgan PF. Hypothermic effects of alkylxanthines: evidence for a calcium-independent phosphodiesterase action. Eur J Pharmacol 1991;204:15-20.
22. Carney JM, Cao W, Logan L, Rennert OM, Seale TW. Differential antagonism of the behavioral depressant and hypothermic effects of 5′-(N- ethylcarboxamide) adenosine by theobromine. Pharmacol Biochem Behav 1986;25:769-73.
23. Walton K, Dorne JL, Renwick AG. Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. Food Chem Toxicol 2001;39:667-80.
24. Carney JM, Holloway FA, Modrow HE. Discriminative stimulus properties of methylxanthines and their metabolites in rats. Life Sci 1985;36:913-20.
25. Stocker M. Ca(2+)-activated K+ channels: molecular determinants and function of the SK family. Nat Rev Neurosci 2004;5:758-70.
26. Kanbayashi T, Honda K, Kodama T, Mignot E, Nishino S. Increased dopaminergic transmission mediates wake-promoting effects of amphetamine isomers. Soc Neurosci Abstract 1998;23:954.
27. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-94.
28. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-9.
29. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications In the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005;9:269-310.
30. American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed. Diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine, 2005.